Flicking the switch in myeloma MRD

Article Hematology

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesus San-Miguel et al.

Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, daratumumab-based therapy reduces the risk of disease progression or death. MRD-negative status and sustained MRD negativity are associated with improved progression-free survival, and daratumumab-based therapy improves rates of MRD negativity lasting 6 or 12 months.

BLOOD (2022)

Add to Collection

Review Hematology

The potential role of mass spectrometry for the identification and monitoring of patients with plasma cell disorders: Where are we now and which questions remain unanswered?

Hannah Giles et al.

Summary: Mass spectrometry techniques offer a highly sensitive method for evaluating and monitoring paraproteins compared to standard electrophoretic techniques, providing valuable insights for clinical assessment and clinical trial enrollment. The increased sensitivity of these assays helps detect and monitor monoclonal proteins more effectively and can increase detection rates of low-level monoclonal proteins.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Ruth M. de Tute et al.

Summary: This study found that MRD status at ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS in patients with multiple myeloma. Lenalidomide maintenance therapy can increase the likelihood of converting from MRD-positive to MRD-negative. However, high-risk molecular features still have a negative impact on PFS and OS.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Hematology